Solid tumors represent abnormal tissue masses where surgical resection is often the primary treatment. However, positive margins increase local recurrence. Near-infrared fluorescence (NIRF) can intraoperatively identify solid tumors and assess margins. However, fluorescent light is diffused at depth, resulting in poor localization. Here, we test two lab-built systems (fast-sweep spectroscopic photoacoustic-ultrasound (PAUS) and NIRF multimodal scanning fiber endoscope) in a pilot ex vivo study to localize FDA-approved Tumor Paint® tozuleristide (BLZ-100, Blaze Bioscience, Inc.) tumor-targeted contrast agent in muscle for real-time guidance (tumor excision) by combining them for pre- (PAUS) and intra- (NIRF) operative solid tumor detection.
|